news

Intestinal bacteria found to produce SARS-CoV-2-inhibiting compounds

Researchers have screened bacteria in the gut, finding that Bifidobacteria have inhibitory activity against SARS-CoV-2.

Compounds in intestine against SARS-CoV-2

Researchers from Yonsei University, South Korea, have found that certain commensal bacteria that reside in the human intestine produce compounds that can inhibit SARS-CoV-2

According to the researchers, previous clinical findings have shown that some patients with moderate to severe COVID-19 have gastro-intestinal symptoms, while others showed signs of infection solely in the lungs.

“We wondered whether gut resident bacteria could protect the intestine from invasion of the virus,” said Mohammed Ali, a PhD student who worked on the study.

 

Access your FREE copy

 


Biomarkers aren’t just supporting drug discovery – they’re driving it

FREE market report

From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.

What you’ll unlock:

  • How biomarkers are guiding dose selection and early efficacy decisions in complex trials
  • Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
  • What makes lab data regulatory-ready and why alignment matters from day one

Explore how biomarkers are shaping early drug development

Access the full report – it’s free!

 

To investigate this hypothesis, the team screened dominant bacteria inhabiting the gut for activity against SARS-CoV-2. Their search revealed that Bifidobacteria, which have previously been shown to suppress other bacteria such as H. pylori and have proven active against irritable bowel syndrome, had such activity.

The investigators also used machine learning to search for potential illness-fighting compounds in databases containing microbially produced molecules, discovering some that might also prove useful against SARS-CoV-2.

“To train our model we leveraged previous coronavirus datasets in which several compounds were tested against targets from coronaviruses,” said Ali. “This approach seems to be significant as those targets share features in common with SARS-CoV-2.”

Ali emphasised the ecological nature of this approach, observing that many existing antibiotics and cancer therapies are compounds that bacteria use to compete with each other within the gastrointestinal tract and that these were initially purified from microbial secretions.

“Finding microbes that secrete anti-coronavirus molecules will be a promising method to develop natural or engineered probiotics to expand our therapeutics prevention techniques, to provide a more sustainable way to combat the viral infection,” said Ali.

The research will be presented at the World Microbe Forum, an online meeting of the American Society for Microbiology (ASM) and the Federation of European Microbiological Societies (FEMS).

Related conditions
,

Related organisations

Related people